About: Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease
Creator	Kim, Su-Mi Park, Jong-Hyeon Choi, Joo-Hyung Jeong, Kwiwan Kim, Byounghan Ko, Mi-Kyeong Ku, Jin-Mo You, Su-Hwa Lyoo, Young
topic	covid:4476687d4a23df5d5428626f81d9621abf94e679#this
Source	Medline; PMC
abstract	In many countries, vaccines are used for the prevention of foot-and-mouth disease (FMD). However, because there is no protection against FMD immediately after vaccination, research and development on antiviral agents is being conducted to induce protection until immunological competence is produced. This study tested whether well-known chemicals used as RNA virus treatment agents had inhibitory effects on FMD viruses (FMDVs) and demonstrated that ribavirin showed antiviral effects against FMDV in vitro/in vivo. In addition, it was observed that combining the administration of the antiviral agents orally and complementary therapy with vaccines synergistically enhanced antiviral activity and preserved the survival rate and body weight in the experimental animals. Antiviral agents mixed with an adjuvant were inoculated intramuscularly along with the vaccines, thereby inhibiting virus replication after injection and verifying that it was possible to induce early protection against viral infection prior to immunity being achieved through the vaccine. Finally, pigs treated with antiviral agents and vaccines showed no clinical signs and had low virus excretion. Based on these results, it is expected that this combined approach could be a therapeutic and preventive treatment for early protection against FMD.
has issue date	2018-11-28(xsd:dateTime)
bibo:doi	10.4142/jvs.2018.19.6.788
bibo:pmid	30304889
has license	cc-by-nc
sha1sum (hex)	4476687d4a23df5d5428626f81d9621abf94e679
schema:url	https://doi.org/10.4142/jvs.2018.19.6.788
resource representing a document's title	Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease
has PubMed Central identifier	PMC6265586
has PubMed identifier	30304889
schema:publication	J Vet Sci
resource representing a document's body	covid:4476687d4a23df5d5428626f81d9621abf94e679#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/4476687d4a23df5d5428626f81d9621abf94e679
is schema:about of	named entity 'ADDITION' named entity 'INJECTION' named entity 'RIBAVIRIN' named entity 'VIVO' named entity 'EFFECTS' named entity 'VACCINE' named entity 'VACCINATION' named entity 'COUNTRIES' named entity 'VACCINES' named entity 'BEING' named entity 'IMMUNOLOGICAL' named entity 'COMBINED' named entity 'EXPERIMENTAL' named entity 'THERAPEUTIC' named entity 'CHEMICALS' named entity 'PRIOR TO' named entity 'PREVENTION OF' named entity 'EXPECTED' named entity 'EXCRETION' named entity 'BASED' named entity 'TREATED WITH' named entity 'FMDV' named entity 'FMD' named entity 'COMPETENCE' named entity 'synergistically' named entity 'effects' named entity 'viral infection' named entity 'agents' named entity 'antiviral' named entity 'vaccines' named entity 'antiviral agents' named entity 'vaccines' named entity 'Synergistic' named entity 'RIBAVIRIN' covid:arg/4476687d4a23df5d5428626f81d9621abf94e679 named entity 'FOOT-AND-MOUTH DISEASE' named entity 'VIRUS REPLICATION' named entity 'IMMUNITY' named entity 'DEMONSTRATED' named entity 'MIXED' named entity 'LOW' named entity 'ORALLY' named entity 'IN VITRO' named entity 'VIRAL INFECTION' named entity 'VIRUS' named entity 'EARLY' named entity 'EFFECT' named entity 'VACCINE' named entity 'STAGE' named entity 'PROTECTION' named entity 'INFECTION' named entity 'SYNERGISTIC' named entity 'PREVENTIVE TREATMENT' named entity 'ANIMALS' named entity 'VERIFYING' named entity 'IMMEDIATELY' named entity 'VIRUSES' named entity 'ADJUVANT' named entity 'OBSERVED' named entity 'RESULTS' named entity 'ENHANCED' named entity 'STUDY' named entity 'SURVIVAL RATE' named entity 'APPROACH' named entity 'USED' named entity 'THESE' named entity 'FOOT-AND-MOUTH DISEASE' named entity 'NO CLINICAL SIGNS' named entity 'POSSIBLE' named entity 'TREATMENT' named entity 'INDUCE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software